HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MBAI
Check-Cap Ltd. Ordinary Share
There isn't enough reported data to score MBAI yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MBAI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
MBAI's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MBAI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 0.5x | $2.09 | — |
| Cheap | 0.7x | $3.31 | +58% |
| Fair | 2.3x | $10.69 | +412% |
| Expensive | 38x | $177 | +8350% |
Historical ranges are pointers, not guarantees.
MBAI's PE is 0.5x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MBAI Forward outlook
There aren't enough analyst estimates for MBAI to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MBAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2021 | -$4.20 | -106% |
| Q4 2020 | -$42.00 | -1100% |
| Q2 2020 | $70.00 | +2400% |
| Q4 2019 | $4.20 | +$126.00 |
MBAI has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MBAI Quarterly Revenue
MBAI and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
MBAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2023 | -$7.1M | +$1.4M |
| Q2 2023 | -$9.9M | +$762K |
| Q4 2022 | -$8.5M | +$727K |
| Q2 2022 | -$10.7M | -$2.7M |
| Q4 2021 | -$9.3M | -$2.3M |
| Q2 2021 | -$8M | -$1.5M |
| Q4 2020 | -$7M | -$366K |
| Q2 2020 | -$6.5M | -$116K |
MBAI has burned cash in almost every quarter: −$36M over the past year, against −$31M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MBAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MBAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +54.5K shares |
| 1 year | +6.6% | +54.8K shares |
| 3 years | +4447% | +871K shares |
MBAI has 890,318 diluted shares, up 6.6% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MBAI Net Leverage
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MBAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.6 | Oversold |
| Stochastic | 5.4 | Oversold |
MBAI's weekly RSI is 30 (oversold) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MBAI PE vs Healthcare Sector
| Metric | MBAI | Sector median | Relative |
|---|---|---|---|
| PE | 0.5x | 26x | 98% below |
| PE % | 1 | 29 | 28 pts below |
MBAI is trading at 0.5x earnings, a 98% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MBAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.79 | 25% below |
| 20 week MA | $5.67 | 63% below |
| 50 week MA | $9.15 | 77% below |
| 100 week MA | $8.30 | 75% below |
| 200 week MA | $12.3 | 83% below |
MBAI is in a downtrend: it's below all five of its weekly moving averages, and 83% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MBAI on returns for 2026, with the stronger performance.
MBAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $245.0 | $54.0 | -78% |
| 2021 | $54.0 | $103.3 | +91% |
| 2022 | $103.3 | $14.8 | -86% |
| 2023 | $14.8 | $14.6 | -1.4% |
| 2024 | $14.6 | $7.70 | -47% |
| 2025 | $7.70 | $11.8 | +53% |
| 2026 YTD | $11.8 | $2.09 | -82% |
MBAI has finished lower in four of the last six years. It's down 82% so far in 2026.